Ieramilimab (development code LAG525) is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.